Modulating CD39 expression to enhance CAR-T cell therapy against hepatocellular carcinoma

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in modulating the function of CAR-T cells.

Leave a Reply